In Bunia, Ituri, vaccine research is becoming part of the Ebola response, with one question still unanswered: can a vaccine designed for another virus species protect against Bundibugyo? The TUMAINI trial is intended to provide data, not to announce in advance that protection has been achieved.
In Ituri, the response also depends on research
Bunia is the capital of Ituri, a province in the north-east of the Democratic Republic of the Congo. The city is at the heart of a public health response that must identify cases, trace people exposed to the virus and maintain the trust of communities. In this context, a clinical trial does not replace care or prevention measures: it seeks to establish whether new tools can strengthen them.
The stakes extend beyond the borders of the DRC. The country belongs to the East African Community (EAC) and the Southern African Development Community (SADC), two regional organisations whose members cooperate on health issues, among others. The movement of people and links between border areas make regional surveillance important, but this does not mean the epidemic has spread throughout the region.
The Bundibugyo virus is distinct from the Zaire ebolavirus. This difference matters: Ervebo is authorised against disease caused by the Zaire virus, but its ability to protect people against Bundibugyo has not been established. The trial’s launch is therefore not confirmation that it is effective in this context.
Three candidates are to be assessed
The first participant in TUMAINI was vaccinated in Bunia on 23 October 2026, according to information published by the Institute of Tropical Medicine Antwerp and reported by Radio Okapi. The study is being conducted jointly by the DRC’s National Institute for Biomedical Research (INRB) and the University of Antwerp, with the Congolese health ministry leading and overseeing it nationally. The World Health Organization is providing technical and scientific support. The Institute of Tropical Medicine’s announcement of the start of TUMAINI and Radio Okapi’s report from the DRC confirm the date and location of the launch.
TUMAINI is an adaptive phase 2/3 trial. This format allows several candidates to be assessed within the same framework and the protocol to be adjusted as the research progresses. Ervebo is the first candidate to enter the trial. Two other vaccines targeting Bundibugyo specifically, developed by Moderna and by the University of Oxford with the Serum Institute of India, are due to join the study after the necessary preparations.
The trial uses ring vaccination: teams target the contacts of an infected person and others at high risk of exposure. The method aims to protect those closest to transmission chains. It requires rigorous contact tracing and the informed participation of communities. The study is set to assess safety, immune response and the candidates’ ability to prevent disease.
The trial does not yet guarantee an effective vaccine
To date, no vaccine has been approved specifically against the Bundibugyo virus, according to information from the Institute of Tropical Medicine. TUMAINI is intended to help fill this data gap. But administering a first dose indicates only that the study has begun. The results will have to establish whether a candidate is safe and whether it actually protects against this virus species.
This distinction is particularly important for Ervebo. Its authorisation against the Zaire virus does not allow the conclusion that it protects against Bundibugyo. The trial is examining this very uncertainty. Presenting the vaccine as an already proven solution could confuse public health guidance and undermine trust in research.
Conducting the study in the field also depends on practical conditions: identifying contacts quickly, explaining the protocol in languages understood locally and allowing people to ask questions. Exposed people and the communities concerned are not simply conduits for research. Their consent and trust are essential both to the quality of the results and to the response.
The official launch in Bunia took place in the presence of Ituri’s military governor, Major General Gaby Kasongo Mulumba, according to information carried by Congolese media. His presence highlights coordination between provincial and health authorities. It does not, however, alter the research teams’ scientific responsibility or the trial’s regulatory oversight.
A Congolese milestone with regional implications
Findings from TUMAINI could help prepare future responses to Bundibugyo outbreaks in the DRC and neighbouring countries. But the regional significance will depend on the results, their scientific review and decisions by the relevant authorities. At this stage, no timeline for the availability of an effective vaccine can be inferred from the launch.
The next developments to watch are therefore twofold: the addition of the other two candidates to the trial and the publication of sufficiently robust data to inform public health decisions. In Ituri, experimental vaccination is being added to surveillance and prevention tools. It opens a line of research, without replacing care or prejudging the outcome.



